NMN (Nicotinamide mononucleotide)

What Is NMN (Nicotinamide mononucleotide)?

NMN (nicotinamide mononucleotide) is a nucleotide that serves as a direct biosynthetic precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme central to cellular energy metabolism. NAD+ levels decline with age, and NMN is taken in the hope of restoring them for benefits framed around “longevity,” metabolic health, and physical performance. Unlike most longevity supplements, NMN now has a meaningful set of human randomised trials, though these are mostly small and short, and hard clinical outcomes (not just blood NAD+) remain largely unproven.

Evidence

A 2024 systematic review of randomised controlled trials pooled ten NMN trials (437 participants, doses 150–1200 mg/day) and reported that physical-performance parameters such as grip strength and skeletal muscle index were only non-significantly improved, while no serious adverse effects were observed ^{1Reference 1Wen J et al. · 2024Systematic reviewImproved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials — systematic review of randomised controlled trialsView study →}. Multiple trials confirm that oral NMN can raise blood NAD+ levels, but most downstream clinical outcomes have not separated clearly from placebo — i.e. NMN reliably moves the biomarker without yet demonstrating robust disease or ageing benefits. On safety, a randomised, double-blind, placebo-controlled trial found that 1250 mg/day for up to four weeks in 31 healthy adults produced no changes beyond normal physiological variation and no serious adverse events ^{2Reference 2Fukamizu Y et al. · 2022RCTSafety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women — randomised controlled trialView study →}. Popular anti-ageing and “reverse ageing” claims go well beyond what these short trials establish and should be treated as unproven.

Dosage & Safety

Human trials have used roughly 150–1250 mg/day, with 250–900 mg/day common; this range is informational and not a personal recommendation. NMN appears well tolerated in the short trials conducted so far, with low apparent toxicity and no serious adverse events reported at doses up to 1250 mg/day for several weeks ^{1Reference 1Wen J et al. · 2024Systematic reviewImproved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials — systematic review of randomised controlled trialsView study →2Reference 2Fukamizu Y et al. · 2022RCTSafety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women — randomised controlled trialView study →}. However, long-term safety, effects in older or unwell populations, drug interactions, and pregnancy/lactation safety are not established. Note that NMN’s regulatory status as a dietary supplement has been contested in the United States; availability may vary.

References

1. Wen J, et al. (2024). Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials — systematic review of randomised controlled trials. Cureus. https://pubmed.ncbi.nlm.nih.gov/39221308/
2. Fukamizu Y, et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women — randomised controlled trial. Sci Rep. https://pubmed.ncbi.nlm.nih.gov/36002548/